<DOC>
	<DOCNO>NCT01505530</DOCNO>
	<brief_summary>This phase 2 study multicenter , randomize , double-blind , placebo-controlled trial participant locally advanced/inoperable metastatic pancreatic cancer , investigate 2 different dos LY2495655 combination standard care chemotherapy .</brief_summary>
	<brief_title>A Phase 2 Study LY2495655 Participants With Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<criteria>Inclusion : Unresectable metastatic pancreas cancer ; participant previous radical surgery pancreas cancer eligible progression document Participants may receive previous adjuvant treatment gemcitabine without radiotherapy pancreas cancer ECOG ( Eastern Cooperative Oncology Group ) Performance status â‰¤ 2 Adequate organ function Have estimate life expectancy least 12 week judgment investigator , able complete least 2 cycle treatment Ability perform indicate functional performance measure baseline Exclusion : Prior systemic therapy unresectable/metastatic pancreas cancer Any medical psychiatric condition , orthopedic neuromuscular condition could limit participation confound study result Currently take medication consider muscle build performance enhancing ( example , androgen therapy , anabolic steroid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>